$51.05
0.71%
Nasdaq, Jul 03, 07:16 pm CET
ISIN
US74366E1029
Symbol
PTGX

Protagonist Therapeutics, Inc. Stock price

$51.05
-0.01 0.02% 1M
+11.48 29.01% 6M
+12.45 32.25% YTD
+16.55 47.97% 1Y
+43.19 549.49% 3Y
+33.30 187.61% 5Y
+39.35 336.32% 10Y
+39.35 336.32% 20Y
Nasdaq, Closing price Thu, Jul 03 2025
+0.36 0.71%
ISIN
US74366E1029
Symbol
PTGX
Sector
Industry

Key metrics

Basic
Market capitalization
$3.2b
Enterprise Value
$2.6b
Net debt
positive
Cash
$574.4m
Shares outstanding
61.9m
Valuation (TTM | estimate)
P/E
57.4 | negative
P/S
15.2 | 37.9
EV/Sales
12.5 | 31.0
EV/FCF
7.7
P/B
4.6
Financial Health
Equity Ratio
90.7%
Return on Equity
40.8%
ROCE
3.9%
ROIC
18.4%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$207.8m | $83.6m
EBITDA
$30.7m | $-146.5m
EBIT
$27.2m | $-133.6m
Net Income
$56.2m | $-122.6m
Free Cash Flow
$335.3m
Growth (TTM | estimate)
Revenue
-34.0% | -80.8%
EBITDA
-79.5% | -157.3%
EBIT
-81.7%
Net Income
-65.3% | -144.5%
Free Cash Flow
622.6%
Margin (TTM | estimate)
Gross
-
EBITDA
14.8% | -175.3%
EBIT
13.1%
Net
27.0% | -146.7%
Free Cash Flow
161.4%
More
EPS
$0.9
FCF per Share
$5.4
Short interest
11.5%
Employees
126
Rev per Employee
$3.5m
Show more

Is Protagonist Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,967 stocks worldwide.

Protagonist Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Protagonist Therapeutics, Inc. forecast:

15x Buy
88%
2x Hold
12%

Analyst Opinions

17 Analysts have issued a Protagonist Therapeutics, Inc. forecast:

Buy
88%
Hold
12%

Financial data from Protagonist Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
208 208
34% 34%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 40 40
1% 1%
19%
- Research and Development Expense 140 140
11% 11%
68%
31 31
79% 79%
15%
- Depreciation and Amortization 3.47 3.47
261% 261%
2%
EBIT (Operating Income) EBIT 27 27
82% 82%
13%
Net Profit 56 56
65% 65%
27%

In millions USD.

Don't miss a Thing! We will send you all news about Protagonist Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Protagonist Therapeutics, Inc. Stock News

Neutral
Investors Business Daily
6 days ago
Protagonist Therapeutics is taking aim directly at Eli Lilly's obesity treatment with a newly announced drug that uses the same mechanism.
Neutral
Accesswire
10 days ago
Webcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below NEWARK, CA / ACCESS Newswire / June 26, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that the company will host a conference call and webcast to announce its oral obesity development candidate and to share in vitro and pre-clinical proof-of-concept study...
Positive
Seeking Alpha
16 days ago
Protagonist Therapeutics has delivered strong Phase 3 data for both icotrokinra (psoriasis) and rusfertide (polycythemia vera), supporting blockbuster potential. Lucrative partnerships with Johnson & Johnson and Takeda provide significant milestone payments, royalties, and potential for $500M–$1B annual revenue by 2030, I'd speculate. A robust cash position and a promising preclinical obesity p...
More Protagonist Therapeutics, Inc. News

Company Profile

Protagonist Therapeutics, Inc. engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Head office United States
CEO Dinesh Patel
Employees 126
Founded 2006
Website www.protagonist-inc.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today